Lazard Asset Management LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Lazard Asset Management LLC

  • $61.8 Billion
  • Q4 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
SELL
$23.9 - $35.38 $17,781 - $26,322
-744 Reduced 9.21%
7,336 $233,000
Q1 2023

May 15, 2023
SELL
$22.82 - $35.32 $47,419 - $73,394
-2,078 Reduced 20.46%
8,080 $197,000
Q4 2022

Feb 14, 2023
BUY
$25.35 - $31.96 $257,505 - $324,649
10,158 New
10,158 $320,000

Others Institutions Holding CERE

# of Institutions
7
Shares Held
5.01M
Call Options Held
3.3K
Put Options Held
0
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email